# Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026

- Link: https://www.thailand-business-news.com/pr-news/tsingke-highlights-ai-driven-cldn18-2-antibody-discovery-at-ais-2026
- Published: 2026-07-08T21:17:00+07:00
- Author: PR Newswire

MONTPELLIER, France, July 8, 2026 /PRNewswire/ — Tsingke, a provider of integrated
life science research solutions, participated in the Antibody Industrial Symposium(
AIS) 2026, one of Europe’s leading conferences dedicated to therapeutic antibodies
and biotherapeutics. At the event, the company presented its latest advances in 
AI-assisted therapeutic antibody discovery and showcased its comprehensive antibody
development platform at Booth #44.

[⌊Tsingke details its AI-enabled workflow for highly selective CLDN18.2 antibody
discovery and reduced cross-reactivity during a scientific presentation at the Antibody
Industrial Symposium (AIS) 2026.⌉⌊Tsingke details its AI-enabled workflow for highly
selective CLDN18.2 antibody discovery and reduced cross-reactivity during a scientific
presentation at the Antibody Industrial Symposium (AIS) 2026.⌉[
Tsingke details 
its AI-enabled workflow for highly selective CLDN18.2 antibody discovery and reduced
cross-reactivity during a scientific presentation at the Antibody Industrial Symposium(
AIS) 2026.

**AI-Enabled Discovery of Highly Selective CLDN18.2 Antibodies**

As part of the scientific program, Tsingke presented an AI-enabled workflow for 
discovering therapeutic antibodies targeting Claudin 18.2 (CLDN18.2), an emerging
target for gastric cancer and other solid tumors.

The presentation demonstrated how AI-assisted sequence analysis and a proprietary
screening strategy improve target specificity by reducing potential cross-reactivity
with the closely related CLDN18.1 protein, a longstanding challenge in CLDN18.2 
antibody development.

The resulting antibody candidates showed strong specificity and favorable developability,
highlighting the potential of integrating AI with experimental validation to accelerate
therapeutic antibody and antibody-drug conjugate (ADC) development.

**End-to-End Antibody Development Capabilities**

In addition to its scientific presentation, Tsingke showcased its integrated antibody
development platform, covering multiple stages of biologics discovery and development,
including:

 ◦ **Antibody Discovery** using hybridoma, single B-cell, and phage display technologies
   for the identification of high-affinity and highly specific antibodies.
 ◦ **Antibody Engineering** including antibody humanization, affinity maturation,
   and synthetic antibody library construction to accelerate therapeutic antibody
   optimization.
 ◦ **Protein Expression** supported by six expression systems and a rapid gene-to-
   protein workflow for applications including monoclonal antibodies, ADCs, AOCs,
   and in vitro diagnostics (IVD).

"AIS 2026 provided an excellent opportunity to share our latest work in AI-enabled
antibody discovery and connect with researchers across the antibody community," 
said** Chuanting Tan, Senior R&D Engineer at Tsingke**. "As therapeutic antibody
development becomes increasingly complex, integrating computational approaches with
experimental validation can help researchers identify and optimize promising candidates
more efficiently. We will continue to enhance our discovery and development capabilities
to support innovation in biologics research."

Building on these efforts, Tsingke will continue expanding its AI-enabled discovery
platform and integrated biologics capabilities to help researchers accelerate projects
from early target discovery through protein expression and characterization.

**About Tsingke**

[Tsingke Biotech](https://www.tsingke.com/) is a leading innovator in synthetic 
biology, with a mission to build "the world’s great gene factory." Combining proprietary
reagents, consumables, and synthesis equipment with AI-driven molecular manufacturing
technologies, Tsingke Biotech provides efficient and high-quality Tsynth® gene synthesis
services. Its work supports industries ranging from biopharma to agriculture, food,
and environmental sciences.

For news and updates, follow Tsingke Biotech on [LinkedIn](https://www.linkedin.com/company/tsingke/).

Contact: [market@tsingke.com.cn](https://www.thailand-business-news.com/pr-news/market@tsingke.com.cn)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026 ](http://www.prnasia.com/story/archive/5000159_CN00159_0?rand=184833)